Conventional Linear Accelerator Research Articles

2199: Dosimetric comparison of liver SBRT treatments with conventional linear accelerator and CyberKnife

2199: Dosimetric comparison of liver SBRT treatments with conventional linear accelerator and CyberKnife

Evaluation of knowledge-based planning models for male pelvic CBCT-based online adaptive radiotherapy on conventional linear accelerators.

To assess the practicality of employing a commercial knowledge-based planning tool (RapidPlan) to generate adapted intact prostate and prostate bed volumetric modulated arc therapy (VMAT) plans on iterative cone-beam computed tomography (iCBCT) datasets. Intact prostate and prostate bed RapidPlan models were trained utilizing planning data from 50 and 44 clinical cases, respectively. To ensure that refined models were capable of producing adequate clinical plans with a single optimization, models were tested with 50 clinical planning CT datasets by comparing dose-volume histogram (DVH) and plan quality metric (PQM) values between clinical and RapidPlan-generated plans. The RapidPlan tool was then used to retrospectively generate adapted VMAT plans on daily iCBCT images for 20 intact prostate and 15 prostate bed cases. As before, DVH and PQM metrics were utilized to dosimetrically compare scheduled (iCBCT Verify) and adapted (iCBCT RapidPlan) plans. Timing data was collected to further evaluate the feasibility of integrating this approach within an online adaptive radiotherapy workflow. Model testing results confirmed the models were capable of producing VMAT plans within a single optimization that were overall improved upon or dosimetrically comparable to original clinical plans. Direct application of RapidPlan on iCBCT datasets produced satisfactory intact prostate and prostate bed plans with generally improved target volume coverage/conformality and rectal sparing relative to iCBCT Verify plans as indicated by DVH values, though bladder metrics were marginally increased on average. Average PQM values for iCBCT RapidPlans were significantly improved compared to iCBCT Verify plans. The average time required [in mm:ss] to generate adapted plans was 06:09±02:06 (intact) and 07:12±01:04 (bed). This study demonstrated the feasibility of leveraging RapidPlan to expeditiously generate adapted VMAT intact prostate and prostate bed plans on iCBCT datasets. In general, adapted plans were dosimetrically improved relative to scheduled plans, emphasizing the practicality of the proposed approach.

Computational and experimental small field dosimetry using a commercial plastic scintillator detector for the 0.35 T MR-linac

PurposeAlthough plastic scintillator detectors (PSDs) are considered ideal dosimeters for small field dosimetry in conventional linear accelerators (linacs), the impact of the magnetic field strength on the response of the PSD must be investigated. MethodsA linac Monte Carlo (MC) head model for a low-field MR-linac was validated for small field dosimetry and utilized to calculate field output factors (OFs). The MC-calculated OFs were compared with the treatment planning system (TPS)-calculated OFs and measured OFs using a Blue Physics (BP) Model 10 commercial PSD and a synthetic diamond detector. The field-specific correction factors, kQclin,Qmsrfclin,fmsr, were calculated for the PSD in the presence of a 0.35 T and magnetic field. The impact of the source focal spot size and initial electron energy on the MC-calculated OFs was investigated. ResultsGood agreement to within 2 % was found between the MC-calculated OFs and BP PSD OFs except for the 0.415 × 0.415 cm2 field size. The BP PSD kQclin,Qmsrfclin,fmsr correction factors were calculated to be within 1 % of unity. For field sizes ≥1.66 × 1.66 cm2, the MC-calculated OFs were relatively insensitive to the focal spot size and initial electron energy to within 2.5 %. However, for smaller field sizes, the MC-calculated OFs were found to differ up to 9.50 % and 7.00 % when the focal spot size and initial electron energy was varied, respectively. ConclusionsThe BP PSD was deemed suitable for small field dosimetry in MR-linacs without requiring any kQclin,Qmsrfclin,fmsr correction factors.

1139: Fully automated adaptive workflow for H&N treatments with a conventional linear accelerator

1139: Fully automated adaptive workflow for H&N treatments with a conventional linear accelerator

TEAM participation in the irradiation of IROC phantoms for cooperative group clinical trials

The participation of radiation oncology team members in the irradiation of Imaging and Radiation Oncology Core (IROC) phantom for cooperative group clinical trials is essential to comply with the latest quality management philosophy. Medical dosimetrists are expected to develop treatment plans for the irradiation of IROC phantoms. For advanced treatment techniques, such as three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), and volumetric-modulated arc therapy (VMAT), the irradiation of the IROC phantoms serves as quality audit. If successful, the irradiation processes demonstrate that the institution has the knowledge of the protocol, and has the appropriate equipment to comply with the protocol requirements. This article describes three IROC phantoms used for credentialing external beam photon beam therapy, delivered using conventional medical linear accelerators, to the medical dosimetry community. Guidance and strategies for the development of treatment plans are discussed. Our institutional irradiation of the three IROC phantoms, delivered using the Truebeam medical linear accelerator, resulted in consistent dose accuracy to within ±1%. The participation of the team members may reduce the overall published failing rate stated to be about one-third of all participating institutions.

Patterns of quality assurance and treatment planning for stereotactic body radiation therapy in India - A survey.

The use of stereotactic body radiation therapy (SBRT) is an increasing trend in the country. The aim of this study is to gain knowledge on patterns of quality assurance (QA) and treatment planning (TP) aspects with respect to SBRT. A questionnaire with multiple choice was designed to determine practices of SBRT covering areas such as years of experience, type of linear accelerator, tumor-motion strategies, calculation algorithm used in the TP system (TPS), the protocol used for small field dosimetry, the detector used for small field dosimetry and QA, respiratory management during delivery. The survey was sent to all radiotherapy institutes in the country having a minimum of one linear accelerator, and responses were analyzed. From June 2022 to December 2022, 265 responses to the SBRT survey were received with response rate as 60.4%. The most common reason for not adopting SBRT was reported as a lack of capability of treatment machines to deliver SBRT (61.6%). Lung (81.1%) was the most practiced site. The most common delivery unit was a conventional linear accelerator (83%); 6 MV FFF (85.7%) was mostly used energy; volumetric-modulated arc radiotherapy (VMAT) (91.5%) was mostly used delivery technique; most of the equipment (more than 91.5%) used multileaf collimator (MLC) leaf width ≤5 mm. The most popular methods used for motion strategies during computed tomography (CT) were motion-encompassing and breath-hold techniques used by 65 (62.5%) and 62 (59.6%) respondents, respectively. The most popular method used for respiratory management during delivery was breath-hold by 55 (52.4%) respondents. Most TPS are equipped with either Type-C or Type-B algorithms. Heterogeneity was observed in the QA protocol and acceptance criteria for analysis of patient-specific QA. The survey resulted in heterogeneity in QA and TP aspects among users of SBRT and demands for harmonizing the dosimetric aspects of SBRT in the country.

Dosimetric comparison of O-ring versus conventional C-arm linear accelerator for volumetric modulated arc therapy (VMAT) of head and neck cancer and carcinoma cervix patients.

The objective of this study is dosimetric comparison between the O-ring Halcyon and C-arm Clinac iX linac for volumetric modulated arc therapy (VMAT) plans for head & neck (H&N) cancer and carcinoma cervix patients. Total 60 patients of H&N cancer and carcinoma cervix were enrolled prospectively from March 2021 to March 2023. VMAT plans with 6 MV photons for Halcyon and Clinac iX were generated and compared for each patient by dose volume histogram for planning target volume coverage and organ at risk (OAR) sparing. There were no differences in between both the linacs for PTV D2% and D98%, homogeneity index, conformity index, Dmax (maximum dose) and Dmean (mean dose) of OAR. Halcyon had significantly shorter treatment time compared to Clinac iX. Halcyon delivered higher integral dose and monitor units. O-ring Halcyon produces VMAT plans comparable to other C-arm linacs for H&N and carcinoma cervix patients.

Evaluation of intracranial stereotactic treatment plans: a comparison study of CyberKnife and TrueBeam systems

Abstract Background: Stereotactic radiotherapy (SRT) for patients with intracranial tumours are delivered using a dedicated platform or a conventional linear accelerator with a flattening filter-free beam. Materials and methods: This study compares treatment plans with intracranial tumours. A total of 29 patients were treated on CyberKnife and planned using the Accuray Precision. The same structure sets ws then exported to Varian Eclipse, and plans were made using a 6 MV FFF beam. Both plans were compared for parameters of target coverage, homogeneity index (HI), new conformity index (nCI), gradient index, selectivity index (SI), volumetric and OAR doses. Results: The treatment plans made for CyberKnife exhibit better results in terms of nCI (1·168 ± 0·08 versus 1·173 ± 0·077), SI (0·885 ± 0·05 versus 0·877 ± 0·05) and GI (3·64 ± 0·5 versus 4·45 ± 1·25), while HI values are better for TrueBeam. For OAR doses, in 65·5% and 72% of treatment plans, brainstem and optic pathways received lower doses on CyberKnife, respectively. In terms of dose spillage, Truebeam plans are better for very low doses (V5%), while for V10%, V20% and V50% CyberKnife plans are better. Conclusion: CyberKnife is a better modality for the delivery of SRS/SRT to intracranial tumours except for dose homogeneity where TrueBeam offered better results.

Dosimetric comparison of glioblastoma radiotherapy treatment plans on a low-field MRI-guided linear accelerator compared to conventional C-arm linear accelerator

Magnetic resonance imaging (MRI)-guided radiation therapy has proven to provide many benefits such as real-time tracking, dose escalation, and the ability to perform online adaptive therapy. The objective of this study is to compare curative treatment plans for glioblastoma tumors on a low-field MR-guided linac vs a C-arm linac and evaluate if they are comparable in terms of coverage, organ at risk sparing, delivery time, and deliverability. This is a retrospective study that consisted of 15 previously treated patients who received radiation therapy for glioblastoma on a C-arm linac. The CT simulation data used for the original clinical plans was imported into the MR-linac treatment planning system (TPS) and utilized for MR-linac plan generation. The plans were evaluated utilizing the dose volumetric histogram (DVH) and isodose lines, then compared in terms of plan quality consisting of PTV coverage, dose distributions, and OAR constraints. Statistical analysis was performed to compare differences between the two planning techniques. QA was performed on a subset of the plans to verify deliverability. Plans generated on the MR-linac were more heterogenous compared to C-arm linac plans. A statistically significant difference was found in the homogeneity index (HI) and the PTV V105% volume (cc) values. The volume of the normal brain receiving 30 Gy also showed a statistically significant (p = 0.0479) difference, where on average an additional 41.5 cc's of the normal brain tissue received 30 Gy in the MR-linac plans. The maximum dose to the normal brain structure also increased in the MR-linac plans on average by 2.6 Gy (p = 0.0002). Similarly, the average maximum dose to the scalp 4 mm structure was 6.5 Gy higher in the MR-linac plans compared to C-arm linac plans (p = 0.0103). The total MU's were higher in the MR-linac plans compared to the C-arm linac plans (p = 0.0015). Both MR-linac and C-arm linac plans met constraints for PTV coverage and OAR sparing, were deliverable, and resulted to be clinically acceptable. However, our study showed that MR-linac plans were not as conformal or as homogenous as C-arm linac plans utilizing noncoplanar beams.

Treatment of Central Nervous System Tumors on Combination MR-Linear Accelerators: Review of Current Practice and Future Directions.

Magnetic resonance imaging (MRI) provides excellent visualization of central nervous system (CNS) tumors due to its superior soft tissue contrast. Magnetic resonance-guided radiotherapy (MRgRT) has historically been limited to use in the initial treatment planning stage due to cost and feasibility. MRI-guided linear accelerators (MRLs) allow clinicians to visualize tumors and organs at risk (OARs) directly before and during treatment, a process known as online MRgRT. This novel system permits adaptive treatment planning based on anatomical changes to ensure accurate dose delivery to the tumor while minimizing unnecessary toxicity to healthy tissue. These advancements are critical to treatment adaptation in the brain and spinal cord, where both preliminary MRI and daily CT guidance have typically had limited benefit. In this narrative review, we investigate the application of online MRgRT in the treatment of various CNS malignancies and any relevant ongoing clinical trials. Imaging of glioblastoma patients has shown significant changes in the gross tumor volume over a standard course of chemoradiotherapy. The use of adaptive online MRgRT in these patients demonstrated reduced target volumes with cavity shrinkage and a resulting reduction in radiation dose to uninvolved tissue. Dosimetric feasibility studies have shown MRL-guided stereotactic radiotherapy (SRT) for intracranial and spine tumors to have potential dosimetric advantages and reduced morbidity compared with conventional linear accelerators. Similarly, dosimetric feasibility studies have shown promise in hippocampal avoidance whole brain radiotherapy (HA-WBRT). Next, we explore the potential of MRL-based multiparametric MRI (mpMRI) and genomically informed radiotherapy to treat CNS disease with cutting-edge precision. Lastly, we explore the challenges of treating CNS malignancies and special limitations MRL systems face.

Institutional experience report on the target contouring workflow in the radiotherapy department for stereotactic arrhythmia radioablation delivered on conventional linear accelerators.

In stereotactic arrhythmia radioablation (STAR), the target is defined using multiple imaging studies and amultidisciplinary team consisting of electrophysiologist, cardiologist, cardiac radiologist, and radiation oncologist collaborate to identify the target and delineate it on the imaging studies of interest. This report describes the workflow employed in our radiotherapy department to transfer the target identified based on electrophysiology and cardiology imaging to the treatment planning image set. The radiotherapy team was presented with an initial target in cardiac axes orientation, contoured on awideband late gadolinium-enhanced (WB-LGE) cardiac magnetic resonance (CMR) study, which was subsequently transferred to the computed tomography (CT) scan used for treatment planning-i.e., the average intensity projection (AIP) image set derived from a4DCT-via an axial CMR image set, using rigid image registration focused on the target area. The cardiac and the respiratory motion of the target were resolved using ciné-CMR and 4D CT imaging studies, respectively. The workflow was carried out for 6patients and resulted in an internal target defined in standard anatomical orientation that encompassed the cardiac and the respiratory motion of the initial target. An image registration-based workflow was implemented to render the STAR target on the planning image set in aconsistent manner, using commercial software traditionally available for radiation therapy.

Evaluation of single-fraction high dose FLASH radiotherapy in a cohort of canine oral cancer patients.

FLASH radiotherapy (RT) is a novel method for delivering ionizing radiation, which has been shown in preclinical studies to have a normal tissue sparing effect and to maintain anticancer efficacy as compared to conventional RT. Treatment of head and neck tumors with conventional RT is commonly associated with severe toxicity, hence the normal tissue sparing effect of FLASH RT potentially makes it especially advantageous for treating oral tumors. In this work, the objective was to study the adverse effects of dogs with spontaneous oral tumors treated with FLASH RT. Privately-owned dogs with macroscopic malignant tumors of the oral cavity were treated with a single fraction of ≥30Gy electron FLASH RT and subsequently followed for 12 months. A modified conventional linear accelerator was used to deliver the FLASH RT. Eleven dogs were enrolled in this prospective study. High grade adverse effects were common, especially if bone was included in the treatment field. Four out of six dogs, who had bone in their treatment field and lived at least 5 months after RT, developed osteoradionecrosis at 3-12 months post treatment. The treatment was overall effective with 8/11 complete clinical responses and 3/11 partial responses. This study shows that single-fraction high dose FLASH RT was generally effective in this mixed group of malignant oral tumors, but the risk of osteoradionecrosis is a serious clinical concern. It is possible that the risk of osteonecrosis can be mitigated through fractionation and improved dose conformity, which needs to be addressed before moving forward with clinical trials in human cancer patients.

Development and Dosimetric Characterization of a Customizable Shield for Subtotal Skin Electron Beam Therapy

Purpose: Subtotal skin electron beam therapy may be an option for patients with cutaneous lymphoma receiving radiation therapy to treat large areas of their skin but may benefit from sparing specific areas that may have had previous radiation therapy, are of specific cosmetic concern, and/or show no evidence of disease. We report here on the design, implementation, and dosimetric characteristics of a reusable and transparent customizable shield for use with the large fields used to deliver total skin electron beam therapy at extended distance with a conventional linear accelerator. A shield was designed and manufactured consisting of acrylic blocks that can be mounted on a steel frame to allow patient-specific shielding. The dosimetry of the device was measured using radiochromic film. The shield is easy to use and well-tolerated for patient treatment, providing minimal electron transmission through the shield with a sharp penumbra at the field edge, with no increase in x-ray dose. We report on the dosimetry of a commercial device that has been used to treat more than 30 patients to date. The customizable shield is well suited to providing patient-specific shielding for subtotal skin electron beam therapy.

Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial—a study protocol

BackgroundPartial breast irradiation (PBI) is standard of care in low-risk breast cancer patients after breast-conserving surgery (BCS). Pre-operative PBI can result in tumor downstaging and more precise target definition possibly resulting in less treatment-related toxicity. This study aims to assess the pathologic complete response (pCR) rate one year after MR-guided single-dose pre-operative PBI in low-risk breast cancer patients.MethodsThe ABLATIVE-2 trial is a multicenter prospective single-arm trial using single-dose ablative PBI in low-risk breast cancer patients. Patients ≥ 50 years with non-lobular invasive breast cancer ≤ 2 cm, grade 1 or 2, estrogen receptor-positive, HER2-negative, and tumor-negative sentinel node procedure are eligible. A total of 100 patients will be enrolled. PBI treatment planning will be performed using a radiotherapy planning CT and -MRI in treatment position. The treatment delivery will take place on a conventional or MR-guided linear accelerator. The prescribed radiotherapy dose is a single dose of 20 Gy to the tumor, and 15 Gy to the 2 cm of breast tissue surrounding the tumor. Follow-up MRIs, scheduled at baseline, 2 weeks, 3, 6, 9, and 12 months after PBI, are combined with liquid biopsies to identify biomarkers for pCR prediction. BCS will be performed 12 months after radiotherapy or after 6 months, if MRI does not show a radiologic complete response. The primary endpoint is the pCR rate after PBI. Secondary endpoints are radiologic response, toxicity, quality of life, cosmetic outcome, patient distress, oncological outcomes, and the evaluation of biomarkers in liquid biopsies and tumor tissue. Patients will be followed up to 10 years after radiation therapy.DiscussionThis trial will investigate the pathological tumor response after pre-operative single-dose PBI after 12 months in patients with low-risk breast cancer. In comparison with previous trial outcomes, a longer interval between PBI and BCS of 12 months is expected to increase the pCR rate of 42% after 6–8 months. In addition, response monitoring using MRI and biomarkers will help to predict pCR. Accurate pCR prediction will allow omission of surgery in future patients.Trial registrationThe trial was registered prospectively on April 28th 2022 at clinicaltrials.gov (NCT05350722).

Application of repeat image analysis to radiation therapy imaging modalities as a quality improvement tool for image guided radiotherapy.

Repeat images contribute to excess patient dose and workflow inefficiencies and can be analyzed to identify potential areas for improvement within a program. Although routinely used in diagnostic imaging, repeat image analysis is not widely used in radiation therapy imaging, despite the role of imaging in the delivery of precise radiation treatments. Repeat image analysis was performed for on-board cone beam CT imagers and CT simulators within a radiation therapy department. Both the rate of repeat images and the reasons for the repeat images were analyzed. Data from nine conventional linear accelerators and three CT simulators were analyzed retrospectively over a 5-month period. Repeated images that were not part of the standard of care were considered repeat images. The repeat rate was expressed as the number of repeat scans as percentage of the total number of scans performed. The reasons for the repeats were collected and classified as either patient preparation, patient setup, patient motion, or machine error. These reasons were further classified into sub-categories. The overall repeat rate across the linear accelerators was 3.3%, with a maximum of 5% on any single machine. The repeat rate for the three CT simulators was 1.5%. The most common reasons for repeat images were patient preparation (incorrect bladder or rectal filling) and patient setup or positioning. Greater positioning challenges led to higher repeat rates on units that treat a large number of breast patients, palliative patients, or pediatric patients. Repeat image analysis can be applied within a radiation therapy department. Establishing baseline repeat rates and analyzing reasons for the repeat images can identify opportunities for improvements in terms of patient dose reduction and workflow efficiency for the program. Periodic repeat image analysis also permits monitoring the program for changes and for comparison against rates at other institutions.

Accuracy of abdominal organ motion estimation in radiotherapy using the right hemidiaphragm top as a surrogate during prolonged breath-holds quantified with MRI.

Respiratory motion presents a challenge in radiotherapy of thoracic and upper abdominal tumors. Techniques to account for respiratory motion include tracking. Using magnetic resonance imaging (MRI) guided radiotherapy systems, tumors can be tracked continuously. Using conventional linear accelerators, tracking of lung tumors is possible by determining tumor motion on kilo voltage (kV) imaging. But tracking of abdominal tumors with kV imaging is hampered by limited contrast. Therefore, surrogates for the tumor are used. One of the possible surrogates is the diaphragm. However, there is no universal method for establishing the error when using a surrogate and there are particular challenges in establishing such errors during free breathing (FB). Prolonged breath-holding might address these challenges. The aim of this study was to quantify the error when using the right hemidiaphragm top (RHT) as surrogate for abdominal organ motion during prolonged breath-holds (PBH) for possible application in radiation treatments. Fifteen healthy volunteers were trained to perform PBHs in two subsequent magnetic resonance imaging (MRI) sessions (PBH-MRI1 and PBH-MRI2). From each MRI acquisition, we selected seven images (dynamics) to determine organ displacement during PBH by using deformable image registration (DIR). On the first dynamic, the RHT, right and left hemidiaphragm, liver, spleen and right and left kidney were segmented. We used the deformation vector fields (DVF), generated by DIR, to determine the displacement of each organ between two dynamics in inferior-superior (IS), anterior-posterior (AP), left-right (LR) direction and we calculated the 3D vector magnitude (|d|). The displacements of the RHT, both hemidiaphragms and the abdominal organs were compared using a linear fit to determine the correlation (R2 of the fit) and the displacement ratio (DR, slope of the fit) between displacements of the RHT and each organ. We quantified the median difference between the DRs of PBH-MRI1 and PBH-MRI2 for each organ. Additionally, we estimated organ displacement in the second PBH by applying the DR from the first PBH to the displacement of the RHT measured during the second PBH. We compared the estimated organ displacement to the measured organ displacement during the second PBH. The difference between the two values was defined as the estimation error of using the RHT as a surrogate and assuming a constant DR over MRI sessions. The linear relationships were confirmed by the high R2 values of the linear fit between the displacements of the RHT and the abdominal organs (R2 > 0.96) in the IS and AP direction and |d|, and high to moderate correlations in the LR direction (0.93 > R2 > 0.64). The median DR difference between PBH-MRI1 and PBH-MRI2 varied between 0.13 to 0.31 for all organs. The median estimation error of the RHT as a surrogate varied between 0.4 and 0.8 mm/min for all organs. The RHT could serve as an accurate surrogate for abdominal organ motion during radiation treatments, e.g. in tracking, provided the error of the RHT as motion surrogate is taken into account in the margins. The study was registered in the Netherlands Trial Register (NL7603). This article is protected by copyright. All rights reserved.

Optimization of the regularization parameter in the Dual Annealing method used for the reconstruction of energy spectrum of electron beam generated by the AQURE mobile accelerator

IntroductionThe shape of the energy spectrum is an essential component of any electron beam Monte Carlo model. Due to specialized equipment and the long measurement time for the direct methods for determining the energy spectrum, attractive alternatives are backward spectrum reconstructions from the measured data. One such approach is solving the first-degree Fredholm integral equation with appropriate regularization. It makes it possible to calculate the depth distribution as the sum of the distributions from monoenergetic beams. This study aims to determine the optimal value of the regularization parameter for the problem of determining the spectrum of the electron beam produced by a mobile accelerator used during intraoperative radiotherapy. Material and methodsThe Geant4 package was used to generate the distributions of deep doses for monoenergetic beams for two models with different degrees of complexity, i.e. simple (theoretical) and full (for the mobile accelerator). The dose distributions for four different shapes of energy spectrum (for each model) were obtained similarly. They were established as the reference data for further calculations. The Dual Annealing optimization method was used to obtain the reconstructed spectrum. The multiple optimizations that differ by the regularization parameter (ranging from 0 to 1) were performed. For each reconstruction, similarity indicators of the energy spectrum and the dose distribution to the referenced data were calculated to determine the optimal regularization parameters. ResultsOptimal regularization parameters determined by similarity indicators for the spectrum and the dose distribution differ for geometry models considered in the study. The regularization parameter for the simple geometry ranged from 0.03 to 0.05, while for full geometry, they were from 0.05 to 0.06. The results for conventional linear accelerators found in the literature range from 0.5 to 1.1. ConclusionThe Dual Annealing optimization method can be effectively used to solve the Fredholm equation with Tikhonov regularization to reconstruct an electron beam's energy spectrum. The regularization parameter value depends on the beam-forming system. Its value for the mobile accelerator considered in the study ranges from 0.05 to 0.06, depending on the nominal beam energy value.

Individual elective lymph node irradiation for the reduction of complications in head and neck cancer patients (iNode): A phase-I feasibility trial protocol

IntroductionThe long-term complication rate in head-and-neck squamous cell carcinoma (HNSCC) patients caused by radiotherapy (RT) can be decreased by restricting elective neck irradiation (ENI) from large adjacent lymph node levels to only individual elective lymph nodes. The primary objective of this study is to treat the first HNSCC patients with individual elective lymph node irradiation by means of a Magnetic Resonance-linac (MR-linac) in order to assess the feasibility. Methods and analysisIn this phase I feasibility study, 20 patients will be included with histologically proven cT2-4N0-1M0 HNSCC originating from the oropharynx, hypopharynx or larynx, planned for treatment with primary radiotherapy and bilateral elective neck irradiation (ENI). Patients will be treated with 35 fractions in six weeks, according to the DAHANCA schedule. Individual lymph nodes inside the conventional lymph node levels will be categorized in low-risk, intermediate-risk and high-risk based on cytology, histology and imaging parameters. Low-risk and intermediate-risk lymph nodes will irradiated in 20 and 23 fractions respectively, with a fraction dose of 2 Gy (=40/46 Gy EQD2). The high-risk lymph nodes and the primary tumor will be irradiated in 35 fractions of 2 Gy (=70 Gy equivalent dose in 2 Gy fractions (EQD2)). To limit treatment burden, 20 fractions will be applied on the MR-linac. The last 15 fractions (sequential boost at the primary tumor, intermediate-risk and high-risk lymph nodes) will be applied on a conventional linear accelerator. The main study endpoint is the percentage of fractions that are successfully completed on the MR-linac. Ethics and disseminationWith individual elective lymph node irradiation we expect less toxicity and a better quality of life for HNSCC patients. However, as the treatment time on the MR-linac will be longer (30–45 vs 15 min per fraction) we need to examine if patients can endure this new treatment concept.

X-ray Target Shielding and Leakage Radiation Inside the Treatment Capsule of the Zap-X.

The ZAP-X represents the first-of-its-kind "self-shielded" therapeutic radiation device, which by novelty, challenges regulators to accommodate it within the existing regulatory framework for radiation protection. To facilitate informed regulatory interpretation, X-ray radiation leakage from the ZAP-X was measured inside the shielded treatment capsule at the level of the patient and X-ray target plane. Measurements were performed on a clinically commissioned system calibrated for reference conditions to deliver 1cGy/MU. Radiation was measured with a FLUKE 451 survey meter and a RadCal ionization chamber as both exposure and dose and presented as a percentage of the system reference dose. Measurements were taken at thirteen locations, eight in the patient plane and five in the X-ray target plane. The results showed a maximum X-ray leakage of 0.000986% in the patient plane and 0.000907% in the target plane. These results are 30 - 100 times lower than existing recommendations as referenced by IEC guidelines standard 60601-2-1 (2020) for radiotherapy linear accelerators (LINACs). Although most conventional LINACs apply a safety factor of 2-5 to the design of collimator shielding and patient dose sparing, the ZAP-X delivers less than 10% of the patient whole body dose compared to this standard, originating from the X-ray target. Even though the ZAP-X intensity modulated radiation therapy (IMRT) factor is significantly higher than conventional Linacs, the absolute dose originating from leakage radiation remains lower by 25. The amount of unintended dose received by the patient's body distant from the isocenter is of interest from the perspective of both clinical and radiation safety. As this whole-body dose is decreased, the resulting treatment-related cancer incidence and mortality rates are decreased accordingly.

Implementation of pencil beam redefinition algorithm (PBRA) for intraoperative electron radiation therapy (IOERT) treatment planning

PurposeSimilar to other radiation therapy techniques, intraoperative electron radiation therapy (IOERT) can benefit from an online treatment planning system (TPS). Among all the analytical electron dose calculation algorithms, pencil beam redefinition algorithm (PBRA) has shown an acceptable accuracy in inhomogeneities. The input dataset for PBRA includes electron planar fluence, mean direction and root mean square (RMS) spread about the mean direction which had been introduced based on the conventional linear accelerator geometry in former studies. Herein, three methods for implementing PBRA for IOERT system are presented. MethodsThe initialization parameters were identified using Monte Carlo (MC) simulation of a dedicated IOERT system equipped with a cylindrical 10 cm applicator, irradiating a water phantom. Phase space distribution of electrons was recorded on a plane below the applicator. The input dataset was extracted for 2 × 2 mm2 pixels and energy bin width of 1 MeV. ResultsPBRA was implemented with three initialization methods and compared to MC. The 3D gamma analysis of the algorithm with the Formula method, which was in best agreement with MC in a simple water phantom, showed passing rates of more than 99 % for all nominal energies and it was 97.1 % for 8 MeV in the presence of protecting disk and irregular surface. Implementing PBRA on CUDA C++ resulted in 5 s run time for 8 MeV nominal energy in a water phantom. ConclusionsThe agreement between PBRA dose calculation and MC is promising for the development of an intraoperative TPS for IOERT.